Trials / Active Not Recruiting
Active Not RecruitingNCT06197802
Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women
An Observational Study to Compare Plateau Antibody Levels of a Recombinant (E.Coli) Human Papillomavirus Nonavalent (Type 6/11/16/18/31/33/45/52/58) Vaccine Versus Gardasil®9 in Healthy Females 18-26 Years of Age
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 392 (estimated)
- Sponsor
- Xiamen University · Academic / Other
- Sex
- Female
- Age
- 20 Years – 28 Years
- Healthy volunteers
- Accepted
Summary
This study is designed to compare plateau antibody levels of a novel recombinant human papillomavirus vaccine (types 6,11,16,18,31,33,45,52,58 )(E.Coli) manufactured by Xiamen Innovax Biotech CO., Ltd., with Gardasil®9 in females 18-26 Years of Age.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli) | Three doses administered intramuscularly at 0, 45 day and 6 month. |
| BIOLOGICAL | Gardasil®9 | Three doses administered intramuscularly at 0, 45 day and 6 month. |
Timeline
- Start date
- 2023-12-30
- Primary completion
- 2024-04-05
- Completion
- 2025-09-01
- First posted
- 2024-01-09
- Last updated
- 2025-07-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06197802. Inclusion in this directory is not an endorsement.